Director · Xeris Biopharma Holdings, Inc. · Xeris Biopharma Holdings, Inc. — Stock Option (Right to Buy)
Side
A
Value
$320K
Shares
31.5K
Price
$10.17
Executed
Nov 2, 2026
Disclosed
Nov 4, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Nov 2 executedNov 4, 2026 disclosed
XERS · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+7 / 25
$320K reported value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Xeris Biopharma Holdings, Inc. — Stock Option (Right to Buy)
Ticker
XERS
Shares
31.5K
Price per share
$10.17
Value
$320,345
Execution date (reported)
Nov 2, 2026
Owned after transaction
31.5K shares
Days from execution to publication
2
Calculation
Value = shares × reported price per share
Shares: 31.5K
Price: $10.17
= $320,345
What this establishes
Taddese Menassie filed this Form 4 reporting a grant or award of XERS on Nov 2, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director
Taddese Menassiecik:0001848805
Issuer
Xeris Biopharma Holdings, Inc.cik:0001867096
Revision history · 0
No field has changed since this record was first ingested.
